Grant: Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
University of Toronto
$105,000.00
Strategies to facilitate eradication of the HIV latent reservoir
EF 2012-13
Résumé
Highly Active Antiretroviral Therapy (HAART) has been tremendously successful in controlling HIV replication in infected individuals but it is not a cure. Persons living with HIV need strict adherence to the drug regimen for the rest of their lives to control the virus. If treatment becomes irregular, the once suppressed viral load can resurge rapidly and resume disease progression. Viral outgrowth is due to the presence of long-lived HIV infected cells that escape the killer T cells responsible for eliminating infected cells that are referred to as the latent HIV reservoir. To cure HIV, new therapies need to be designed that can bring these cells out of hiding so that they may be detected and killed by killer T cells. In my research projects I propose two such new strategies. Firstly, studies suggest that latently infected cells express highest amounts of a protein named Tim-3 upon their surface that keeps HIV replication repressed to extremely low levels or none such that the infected cell does not attract a killer T cell towards it. By blocking this Tim-3 protein, I aim to reverse this viral replication brake and thus selectively induce viral outgrowth enough from latently infected cells so that they may be detected and eradicated by killer T cells. Secondly, I wish to suppress the functions of an HIV protein called Nef that is enriched in latently infected cells once they are reactivated. Nef protects these cells from early detection by killer T cells by reducing the expression of another protein called MHC-I that is required for killer T cells to recognize an infected cell. Through collaboration I have acquired novel drugs that help prevent Nef's negative effect on the latently infected cell. By treating these latently infected cells with these new drugs we hope to enhance killer T cells' ability to kill an infected cell. The aim of both of these strategies is to provide a new avenue of HIV therapy that could eventually eradicate HIV and thus cure the patient.
Programme
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
272905
Name
Mujib Shariq
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Strategies to facilitate eradication of the HIV latent reservoir
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Keyworddelim
Eliminating Hiv Latent Reservoir; Enhancing Ctl Response; Hiv Latency; Hiv Nef; Hiv/Aids; Immune Evasion; Immune Exhaustion/Tolerance; Nef Mhc-I Downregulation
Abstract
Highly Active Antiretroviral Therapy (HAART) has been tremendously successful in controlling HIV replication in infected individuals but it is not a cure. Persons living with HIV need strict adherence to the drug regimen for the rest of their lives to control the virus. If treatment becomes irregular, the once suppressed viral load can resurge rapidly and resume disease progression. Viral outgrowth is due to the presence of long-lived HIV infected cells that escape the killer T cells responsible for eliminating infected cells that are referred to as the latent HIV reservoir. To cure HIV, new therapies need to be designed that can bring these cells out of hiding so that they may be detected and killed by killer T cells. In my research projects I propose two such new strategies. Firstly, studies suggest that latently infected cells express highest amounts of a protein named Tim-3 upon their surface that keeps HIV replication repressed to extremely low levels or none such that the infected cell does not attract a killer T cell towards it. By blocking this Tim-3 protein, I aim to reverse this viral replication brake and thus selectively induce viral outgrowth enough from latently infected cells so that they may be detected and eradicated by killer T cells. Secondly, I wish to suppress the functions of an HIV protein called Nef that is enriched in latently infected cells once they are reactivated. Nef protects these cells from early detection by killer T cells by reducing the expression of another protein called MHC-I that is required for killer T cells to recognize an infected cell. Through collaboration I have acquired novel drugs that help prevent Nef's negative effect on the latently infected cell. By treating these latently infected cells with these new drugs we hope to enhance killer T cells' ability to kill an infected cell. The aim of both of these strategies is to provide a new avenue of HIV therapy that could eventually eradicate HIV and thus cure the patient.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mujib, Shariq
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~